Massachusetts
Cancer clinical trials in Massachusetts
503 cancer studies are recruiting participants at sites in 31 cities across Massachusetts as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Massachusetts city with a recruiting study
By research area: Breast Cancer (152), Lung Cancer (143), Lymphoma (108), Prostate Cancer (53), Pancreatic Cancer (27), Melanoma (20).
Boston (467), Worcester (28), Burlington (24), Springfield (14), Peabody (13), Foxborough (11), Beverly (10), Methuen (10), Milford (10), South Weymouth (10), Gloucester (9), Newton (7), Brighton (5), Stoneham (5), Lowell (4), Weymouth (4), Winchester (4), Newburyport (3), Danvers (2), Plymouth (2), Brookline (1), Fairhaven (1), Fall River (1), Holyoke (1), Hyannis (1), Jamaica Plain (1), Pittsfield (1), Salem (1), Wellesley Hills (1), Woburn (1), Worester (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Massachusetts
Basic details from each study's public record (the 12 most recently updated of 503). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Recruiting in
- Boston
- Registry record
- NCT06324357 · updated
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Boston
- Registry record
- NCT06686394 · updated
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Recruiting in
- Boston
- Registry record
- NCT05696626 · updated
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Boston
- Registry record
- NCT05894239 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Massachusetts on ClinicalTrials.gov.
Lung cancer: recently updated in Massachusetts
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- Erasca, Inc.
- Recruiting in
- Boston
- Registry record
- NCT06983743 · updated
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Recruiting in
- Worcester
- Registry record
- NCT05920356 · updated
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
- No phase
- Ages 40 to 80
- All sexes
- Sponsor
- Dana-Farber Cancer Institute
- Recruiting in
- Boston
- Registry record
- NCT06716580 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Massachusetts on ClinicalTrials.gov.
Prostate cancer: recently updated in Massachusetts
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
- No phase
- Ages 55 to 69
- Male participants
- Sponsor
- VA Office of Research and Development
- Recruiting in
- Boston
- Registry record
- NCT05926102 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Massachusetts on ClinicalTrials.gov.
Melanoma: recently updated in Massachusetts
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Boston
- Registry record
- NCT02332668 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Massachusetts on ClinicalTrials.gov.
Lymphoma: recently updated in Massachusetts
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- No phase
- Ages 1 to 25
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Boston
- Registry record
- NCT05621291 · updated
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Boston
- Registry record
- NCT06806033 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Massachusetts on ClinicalTrials.gov.
Pancreatic cancer: recently updated in Massachusetts
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Boston
- Registry record
- NCT04924075 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Massachusetts on ClinicalTrials.gov.
Ask about studies in Massachusetts
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections